1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 38 pages

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Kolltan Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kolltan Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kolltan Pharmaceuticals, Inc.
- The report provides overview of Kolltan Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Kolltan Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Kolltan Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Kolltan Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kolltan Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kolltan Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Kolltan Pharmaceuticals, Inc. Snapshot 5
Kolltan Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Kolltan Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Kolltan Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance 11
Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Kolltan Pharmaceuticals, Inc. - Drug Profiles 14
KTN-0158 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
KTN-3379 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
KIT-SG3227 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
KTN-0182A 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibody Conjugate to Antagonize ALK Receptor for Oncology 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Monoclonal Antibody Conjugate to Inhibit Axl for Cancer, Inflammation and Infection 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Monoclonal Antibody Conjugate to Target ErbB-3 for Oncology 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Monoclonal Antibody to Inhibit c-MET for Cancer 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Monoclonal Antibody to Inhibit FGFR4 for Cancer 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Monoclonal Antibody to Inhibit RON for Cancer 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Kolltan Pharmaceuticals, Inc. - Pipeline Analysis 29
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target 29
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 30
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 31
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 32
Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates 33
Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries 36
Head Office 36
Other Locations and Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Kolltan Pharmaceuticals, Inc., Key Information 5
Kolltan Pharmaceuticals, Inc., Key Facts 5
Kolltan Pharmaceuticals, Inc. - Pipeline by Indication, 2016 7
Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 9
Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 10
Kolltan Pharmaceuticals, Inc. - Phase I, 2016 11
Kolltan Pharmaceuticals, Inc. - Preclinical, 2016 12
Kolltan Pharmaceuticals, Inc. - Discovery, 2016 13
Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016 29
Kolltan Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 30
Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 31
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 32
Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 33
Kolltan Pharmaceuticals, Inc., Subsidiaries 36

List of Figures
Kolltan Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 7
Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 9
Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 10
Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016 29
Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 31
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.